H2020Индивидуална стипендия2015–2017

NeuroRhomboid · Discovering the signalling pathways and physiology of active rhomboid proteases in the brain

„Хоризонт 2020“ — Действия „Мария Склодовска-Кюри“

Период
2015-04-07 → 2017-04-06
Финансиране от ЕС
183 455 €
Участници
1
Схема
MSCA-IF-EF-ST

Линиите свързват координатора с партньорите.

Накратко на български

Ромбоидните протеази в мозъка разсичат специфични протеини, като например RHBDL4 влияе върху протеина APP. Разбирането на тези процеси помага да се разбере механизмът на заболявания като Алцхаймер и Паркинсон.

Този кратък обзор е генериран от изкуствен интелект

Кратко обяснение, генерирано от езиков модел по текста на CORDIS. Оригиналът е по-долу.

Резултати накратко

Discovering the signalling pathways and physiology of active rhomboid proteases in the brain

Protease enzymes catalyse irreversible post-translational modifications that control many distinct cellular processes. An important class are intramembrane proteases, which have catalytic activity that is confined within the lipid bilayer. Intramembrane proteases function to cleave their specific transmembrane substrates. To our knowledge, the human genome encodes fourteen intramembrane proteases, of which five are rhomboid proteases. Rhomboid proteases are defined and characterised by their distinct mode of catalysis (a catalytic dyad of serine and histidine residues) and their evolutionarily conserved six-transmembrane domain core structure. Despite their intensive study, we do not know the physiological roles for mammalian rhomboid proteases; in particular few roles have been ascribed for the four rhomboids that are localised within the secretory pathway. This is mainly due to a lack of identified substrates. The core aim of this project is to identify novel substrates for rhomboid proteases, to enable us to expose their physiological and medical significance. Several intramembrane proteases have been linked to human pathologies such as neurodegeneration and cancer. Perhaps the most well known example is that of gamma-secretase and its pivotal role in the formation and accumulation of beta-amyloid, which characterises Alzheimer’s Disease. Interestingly, rhomboid proteases have also been linked to Alzheimer’s Disease; RHBDL4 has been shown to process APP but in a distinct manner to that of gamma-secretase. Furthermore, PARL, the mitochondrially targeted rhomboid protease, cleaves PINK1, a mitochondrial kinase mutated in Parkinson’s Disease. Overall, these examples illustrate the potential impact that can be made by the discovery of a protease-substrate relationship. Rhomboid proteases are present in all kingdoms of life. Such conservation throughout evolution suggests these enzymes have important functions in human biology, which are only now being illuminated, and can only be fully comprehended through substrate discovery. The overall objective of the action is to discover the physiological and medical significance of active rhomboid proteases in mammals. Two largely uncharacterised rhomboids are enriched in the brain, and are the main focus of our investigations. To achieve our objective, we work toward three goals: 1) to identify novel substrates for the rhomboid proteases, 2) to validate the identified substrates biologically and 3) to uncover their physiological significance through the screening of mutant cells and model organisms.

Текст от CORDIS, на английски · Данни: CORDIS, © Европейски съюз

Цел на проекта

Proteases control major pathways in the nervous system and aberrant proteolysis underlies many neurobiological disorders and diseases e.g. Alzheimer's and Parkinson's disease. Signal generation and release is tightly regulated by protease activity, as many key signalling factors are synthesised as transmembrane precursors that require cleavage to liberate their active ectodomains. The largest family of intramembrane proteases are the newly discovered rhomboids, which are found in all kingdoms of life. To date, their physiological significance in mammals is largely unknown, as is the substrate-selectivity of most mammalian rhomboids. I have exciting preliminary data that two uncharacterised mammalian rhomboids, RHBDL1 and RHBDL3, are specifically highly expressed in primary neurons in the CNS. Unlike the well-studied RHBDL2 and Drosophila rhomboids 1-3, they do not have activity against EGF-like growth factors, so they are likely to cleave a novel substrate. A major limitation in protease research has been the lack of unbiased and systematic screens for their substrates. Addressing this deficiency, first, I aim to identify RHBDL1/3-dependent substrates in primary neurons, by adapting recently developed biochemical assays, such as SPECS and BioID. My second aim is the mechanistic validation of these substrates. Third, I will be the first to study the physiological role for active rhomboids, using CRISPR-mediated knock-out neurons and mice. By discovering the role and function of RHBDL1/3 in the brain, I will make an important contribution towards the elucidation of the physiological and medical significance of rhomboid proteases in mammals.

Оригинален текст от CORDIS (на английски).

Участници

Връзки

Данни: CORDIS, © Европейски съюз